Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now

Dentsply Sirona's 2026 consensus revenue is projected to decline 3.1% to $3.57 billion and adjusted EPS to fall 2.5% to $1.56, reflecting continued weak equipment, implant and SureSmile demand. Q2 Orthodontic and Implant Solutions sales fell to $197 million from $226 million, while Connected Technology Solutions declined 3.8% in constant currency and Americas sales dropped 11.6%. Tariffs, freight costs and unfavorable mix have pressured margins, with Q1 adjusted EBITDA margin down 430bps and gross margin down 560bps; a $120 million annualized cost-savings plan and digital-dentistry investments provide longer-term offsets.

Analysis

XRAY is a negative operating-leverage setup rather than a simple demand trough: equipment softness removes high-margin utilization and mix, while tariffs/freight create costs that cannot be fully absorbed by a still-fragile distributor channel. The announced cost program is meaningful only if savings arrive ahead of commercial spending; otherwise, reinvestment can mask the benefit and leave consensus margins vulnerable over the next 1-3 quarters. The critical KPI is not new dealer count but sell-through, scanner-to-software attach, and recurring consumables per installed digital workflow.

The competitive read-through favors better-positioned dental incumbents such as ALIGN and HSIC, which have greater channel scale and/or recurring revenue exposure, while XRAY's weak aligner execution gives labs and practices less reason to standardize on its ecosystem. A broader easing in practice financing conditions would be the fastest catalyst, but it could initially benefit the category leaders most because deferred replacement demand typically flows to the strongest installed-base vendors. XRAY's depressed valuation may limit immediate downside, yet a low multiple is not protective if revenue declines persist and restructuring savings are offset by price concessions or further sourcing disruption.

Contrarianly, the market may be underweight the earnings torque if fourth-quarter dealer productivity validates a recovery in digital equipment orders: fixed-cost absorption plus cost actions could produce a sharper-than-expected margin rebound in 2027. That thesis is falsified by another quarter of Americas equipment decline, continued double-digit SureSmile contraction, or gross-margin deterioration despite lower tariff headwinds. The cited positive results in VCYT, INSP and GMED are not comparable substitutes for XRAY; their end-market drivers and valuation sensitivities differ, so they should not be used as a dental-demand proxy.

Key Decisions for Investors

• Maintain an underweight/short bias in XRAY through the next two earnings prints; use any dealer-launch or digital-AI narrative rally to initiate. Target 10-15% downside if revenue estimates reset again; cover if Americas equipment growth turns positive and adjusted EBITDA margin expands sequentially by more than 200 bps.
• Pair long ALIGN / short XRAY over 3-6 months for relative exposure to digital orthodontics: ALIGN has a more established aligner ecosystem, while XRAY bears higher execution and tariff/mix risk. Size modestly because a sharp rate-driven rebound in dental capex could lift both; stop the pair if SureSmile growth improves to flat or better for two quarters.
• Do not treat the restructuring target as earnings until management discloses realized savings, cash restructuring charges, and incremental commercial spend. Set an alert for fourth-quarter distributor sell-through and DS Core recurring-revenue/attach metrics; absent those data, no turnaround long is warranted.
• For healthcare growth exposure, prefer GMED or INSP over XRAY on a 6-12 month horizon, but avoid chasing post-earnings strength without valuation work. Their operating momentum is more independently driven than discretionary dental equipment demand.